Avasimibe inhibiting ACAT can block cholesterol ester synthesis and LD formation, then enhance the anti-tumor effect of CD8+ TILs by increasing membrane synthesis and intracellular free cholesterol levels [172]. Here, ACAT1 is linked to neoplasm.